Goldman Sachs Group Inc. decreased its position in shares of Pulse Biosciences, Inc (NASDAQ:PLSE) by 21.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,115 shares of the company’s stock after selling 4,868 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.13% of Pulse Biosciences worth $626,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Nationwide Fund Advisors acquired a new stake in shares of Pulse Biosciences during the 2nd quarter valued at $177,000. California Public Employees Retirement System acquired a new stake in shares of Pulse Biosciences during the 2nd quarter valued at $297,000. OxFORD Asset Management LLP acquired a new stake in shares of Pulse Biosciences during the 2nd quarter valued at $310,000. Rhumbline Advisers acquired a new stake in shares of Pulse Biosciences during the 2nd quarter valued at $325,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Pulse Biosciences during the 2nd quarter valued at $338,000. 9.69% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Goldman Sachs Group Inc. Sells 4,868 Shares of Pulse Biosciences, Inc (PLSE)” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://sportsperspectives.com/2017/11/11/goldman-sachs-group-inc-sells-4868-shares-of-pulse-biosciences-inc-plse.html.
Shares of Pulse Biosciences, Inc (PLSE) opened at $30.33 on Friday. Pulse Biosciences, Inc has a twelve month low of $5.20 and a twelve month high of $39.50.
Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings data on Tuesday, November 7th. The company reported ($0.52) earnings per share for the quarter.
In other news, major shareholder Robert W. Duggan acquired 2,000,000 shares of the business’s stock in a transaction that occurred on Sunday, September 24th. The shares were bought at an average price of $15.02 per share, with a total value of $30,040,000.00. Following the acquisition, the insider now directly owns 5,797,612 shares in the company, valued at approximately $87,080,132.24. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Mitchell E. Levinson acquired 3,835 shares of the business’s stock in a transaction that occurred on Thursday, September 14th. The shares were purchased at an average cost of $12.30 per share, for a total transaction of $47,170.50. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 2,466,429 shares of company stock worth $36,893,301. 6.70% of the stock is currently owned by company insiders.
Pulse Biosciences Profile
Pulse Biosciences, Inc, formerly Electroblate, Inc, is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue.
Want to see what other hedge funds are holding PLSE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pulse Biosciences, Inc (NASDAQ:PLSE).
Receive News & Ratings for Pulse Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.